Tough choices: the cost-effectiveness of sildenafil.
McGarvey
M R
MR
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000191:economics; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D010879:Piperazines / Q000191:economics* / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D014481:United States
D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases